ZA200809662B - Modified humanised anti-interleukin-18 antibodies - Google Patents

Modified humanised anti-interleukin-18 antibodies

Info

Publication number
ZA200809662B
ZA200809662B ZA2008/09662A ZA200809662A ZA200809662B ZA 200809662 B ZA200809662 B ZA 200809662B ZA 2008/09662 A ZA2008/09662 A ZA 2008/09662A ZA 200809662 A ZA200809662 A ZA 200809662A ZA 200809662 B ZA200809662 B ZA 200809662B
Authority
ZA
South Africa
Prior art keywords
interleukin
antibodies
humanised anti
modified
modified humanised
Prior art date
Application number
ZA2008/09662A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
Ian Kirby
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200809662(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200809662B publication Critical patent/ZA200809662B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
ZA2008/09662A 2006-05-25 2008-11-12 Modified humanised anti-interleukin-18 antibodies ZA200809662B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins
PCT/EP2007/055029 WO2007137984A2 (en) 2006-05-25 2007-05-23 Modified humanised anti-interleukin-18 antibodies

Publications (1)

Publication Number Publication Date
ZA200809662B true ZA200809662B (en) 2014-05-28

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2008/09662A ZA200809662B (en) 2006-05-25 2008-11-12 Modified humanised anti-interleukin-18 antibodies

Country Status (22)

Country Link
US (5) US8133978B2 (enExample)
EP (1) EP2027157B1 (enExample)
JP (1) JP5420399B2 (enExample)
KR (1) KR101416078B1 (enExample)
AR (1) AR061115A1 (enExample)
AU (1) AU2007267213B2 (enExample)
BR (1) BRPI0711908B8 (enExample)
CA (1) CA2652733C (enExample)
CR (1) CR10468A (enExample)
EA (1) EA017303B1 (enExample)
ES (1) ES2514495T3 (enExample)
IL (1) IL194995A0 (enExample)
MA (1) MA30486B1 (enExample)
MX (1) MX2008014842A (enExample)
MY (1) MY157173A (enExample)
NO (1) NO341921B1 (enExample)
NZ (1) NZ572565A (enExample)
PE (1) PE20080262A1 (enExample)
SG (1) SG172625A1 (enExample)
TW (1) TWI422387B (enExample)
WO (1) WO2007137984A2 (enExample)
ZA (1) ZA200809662B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX2008014842A (es) 2006-05-25 2009-02-17 Glaxo Group Ltd Anticuerpos humanizados contra interleuquina-18 modificados.
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
CA2734358A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
BRPI0917165A2 (pt) 2008-08-27 2015-11-17 Hoffmann La Roche método para classificação de anticorpo de alta afinidade
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP5412579B2 (ja) 2009-08-25 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 速度因子
CN102834413A (zh) * 2010-02-09 2012-12-19 葛兰素集团有限公司 代谢障碍的治疗
MX2012011629A (es) * 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
MX351887B (es) * 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2014080866A1 (ja) 2012-11-21 2014-05-30 一般財団法人化学及血清療法研究所 新規なヒト抗ｉｌ－１８抗体
US10259842B2 (en) * 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CA3201637A1 (en) 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
JP7880582B2 (ja) 2021-07-13 2026-06-26 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof
JP2026525821A (ja) 2023-06-20 2026-08-04 アポロ・エイピー４３・リミテッド アトピー性皮膚炎を処置するための抗ｉｌ－１８抗体療法
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease
WO2025262216A1 (en) 2024-06-21 2025-12-26 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins binding to il23 and il18

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
PT528767E (pt) 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP2952750B2 (ja) 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
CN104231078A (zh) * 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
RS51737B (sr) 2000-02-21 2011-10-31 Laboratoires Serono Sa. Korišćenje inhibitora il-18
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
NZ525793A (en) * 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20050074434A1 (en) 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
WO2004097019A1 (ja) 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
BRPI0509367A (pt) 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
MX2008014842A (es) 2006-05-25 2009-02-17 Glaxo Group Ltd Anticuerpos humanizados contra interleuquina-18 modificados.
CA2734358A1 (en) 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists

Also Published As

Publication number Publication date
AR061115A1 (es) 2008-08-06
CA2652733A1 (en) 2007-12-06
BRPI0711908B8 (pt) 2021-05-25
AU2007267213B2 (en) 2012-03-29
BRPI0711908B1 (pt) 2020-08-04
WO2007137984A3 (en) 2008-01-24
US10703814B2 (en) 2020-07-07
US9499617B2 (en) 2016-11-22
US20070292432A1 (en) 2007-12-20
ES2514495T3 (es) 2014-10-28
IL194995A0 (en) 2011-08-01
KR20090023625A (ko) 2009-03-05
KR101416078B1 (ko) 2014-07-07
EP2027157B1 (en) 2014-08-06
US20140105894A1 (en) 2014-04-17
NO341921B1 (no) 2018-02-19
CA2652733C (en) 2016-06-21
PE20080262A1 (es) 2008-04-30
US20120100137A1 (en) 2012-04-26
NZ572565A (en) 2011-04-29
TWI422387B (zh) 2014-01-11
JP2009537608A (ja) 2009-10-29
EP2027157A2 (en) 2009-02-25
BRPI0711908A2 (pt) 2012-01-03
NO20084650L (no) 2008-12-19
MA30486B1 (fr) 2009-06-01
US20190031753A1 (en) 2019-01-31
US20170029497A1 (en) 2017-02-02
US8637018B2 (en) 2014-01-28
MY157173A (en) 2016-05-13
SG172625A1 (en) 2011-07-28
MX2008014842A (es) 2009-02-17
EA200802182A1 (ru) 2009-06-30
EA017303B1 (ru) 2012-11-30
AU2007267213A1 (en) 2007-12-06
CR10468A (es) 2009-01-09
JP5420399B2 (ja) 2014-02-19
TW200808350A (en) 2008-02-16
WO2007137984A2 (en) 2007-12-06
US8133978B2 (en) 2012-03-13

Similar Documents

Publication Publication Date Title
IL194995A0 (en) Modified humanised anti-interleukin-18 antibodies
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
EP2331579A4 (en) MONOCLONAL ANTIBODIES
SG10201601279SA (en) Monoclonal Antibody STRO-4
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
ZA200904022B (en) Monoclonal antibodies against ANGPTL3
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
GB0708002D0 (en) Antibodies
ZA201300949B (en) Humanized anti-factor d antibodies
IL204835A0 (en) Humanized antibody
IL194776A0 (en) Humanized c-kit antibody
PT2146745E (pt) Anticorpo pentaespecífico
IL196806A0 (en) Anti-myostatin antibodies
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
GB0615662D0 (en) Antibody
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
ZA200901481B (en) Smallpox monoclonal antibody
HK1127949A (en) Modified humanised anti-interleukin-18 antibodies
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
GB0706963D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody